Treatment triple-header news from the MedPage Today. From the article:
At the American Society of Clinical Oncology virtual meeting, initial findings from a phase II study were reported on minimum residual disease (MRD)-driven, time-limited therapy with a regimen known as BOVen (zanubrutinib, obinutuzumab, and venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL).
In this exclusive MedPage Today video, study author Jacob Soumerai, MD, of Massachusetts General Hospital Cancer Center in Boston, explains the study results and implications.
At the time of posting, the video with Dr. Soumerai in the link below was not working. (A written transcript is provided) If the video link has not been corrected, I have provided a second link that will take you directly to the video.
medpagetoday.com/meetingcov...
Direct link to the interview video
assets14.ign.com/videos/zen...
Treatment Options keep expanding. Be Safe/Stay Well - cujoe